About this medicine
- Approved name
- Numeta G13%E and Numeta G16%E emulsion for infusion
- Class
- -
About this procedure
- Current status
- CMDh final position
- Reference number
- EMEA/H/A-107i/1373
- Type
- Article 107i procedures
This type of procedure is triggered when a Member State or the European Commission consider that urgent action is necessary because of a safety issue. Situations that fall under this procedure include consideration for suspension or revocation of the marketing authorisation for a medicine, the prohibition of supply of a medicine or major changes to the marketing authorisation such as deletion of indications, reduction of the recommended dose or new contraindications. The procedure is also applicable in case of a safety issue with a class of medicines.
- Authorisation model
- Nationally authorised product(s)
- Decision making model
- PRAC-CMDh
Key dates and outcomes
- Procedure start date
- 13/06/2013
- PRAC recommendation date
- 05/09/2013
- CHMP opinion date
- 18/09/2013
- Outcome
- Suspension